drugset
drugset / Trial / NCT00714688

A Study to Evaluate Effectiveness and Safety of Prolonged Release OROS Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder

NCT00714688 ↗

Phase 3 Completed 279 enrolled Janssen-Cilag International NV
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy of 2 fixed dosages of Prolonged Release (PR) OROS methylphenidate (54 and 72 mg/day) compared with placebo in adult patients with attention deficit/hyperactivity disorder (ADHD).

Timeline

Start
2008-02
Primary completion
2009-04
Completion
2009-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Methylphenidate Small molecule 54 mg Oral
Subject Methylphenidate Small molecule 72 mg Oral

Indications

attention deficit-hyperactivity disorder